Effects and mechanisms of theta burst stimulation targeting individualized pre-supplementary motor area for post-stroke aphasia: study protocol for a randomized controlled trial. [PDF]
Wang D +7 more
europepmc +1 more source
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane +43 more
wiley +1 more source
COMPONENTS OF THE SYSTEM OF PRE -TRIAL INVESTIGATION
openaire +1 more source
INFORMATIVE-COGNITIVE COMPONENT OF A PRE-TRIAL INVESTIGATION
openaire +1 more source
Botulinum Toxin (Dysport) to Prevent Radiation-Induced Dysfunction of Salivary Glands in Head and Neck Cancer. [PDF]
Farhan F +12 more
europepmc +1 more source
Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis
ABSTRACT Paramagnetic rim lesions (PRLs) are a subset of chronic active multiple sclerosis (MS) lesions marked by iron‐laden microglia and macrophages. Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, suppresses acute MS activity, but its effect on PRLs remains unclear. In a longitudinal study of 29 ocrelizumab‐treated patients with at least
Kimberly H. Markowitz +9 more
wiley +1 more source
On the issue of procedural management of pre-trial investigation
B.Zh. Sagymbekov, R.S. Kaliaskarov
openaire +2 more sources
SUSPENSION OF TIME LIMITS OF PRE-TRIAL INVESTIGATION
openaire +1 more source
Autologous SVF therapy modulates neuroinflammation in ALS: phase I trial demonstrating safety and CSF biomarker dynamics. [PDF]
Li R +8 more
europepmc +1 more source
ABSTRACT Objective This analysis evaluates the effect of successful reperfusion on functional outcomes after MT, stratified by admission National Institutes of Health Stroke Scale (NIHSS) and Alberta Stroke Program Early CT Score (ASPECTS) as surrogates for clinical‐core mismatch, using multicenter registry data.
Felix Schlicht +53 more
wiley +1 more source

